Viewpoint

Expanding prostate cancer screening

William J Catalona*, Stacy Loeb, Misop Han

*Corresponding author for this work

Research output: Contribution to journalShort survey

45 Citations (Scopus)

Abstract

Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.

Original languageEnglish (US)
Pages (from-to)441-443
Number of pages3
JournalAnnals of Internal Medicine
Volume144
Issue number6
DOIs
StatePublished - Mar 21 2006

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Prostatic Neoplasms
Biopsy
Prostate
Guidelines

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Catalona, William J ; Loeb, Stacy ; Han, Misop. / Viewpoint : Expanding prostate cancer screening. In: Annals of Internal Medicine. 2006 ; Vol. 144, No. 6. pp. 441-443.
@article{2092b39757cf45789f605a3d99af3e5c,
title = "Viewpoint: Expanding prostate cancer screening",
abstract = "Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.",
author = "Catalona, {William J} and Stacy Loeb and Misop Han",
year = "2006",
month = "3",
day = "21",
doi = "10.7326/0003-4819-144-6-200603210-00012",
language = "English (US)",
volume = "144",
pages = "441--443",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

Viewpoint : Expanding prostate cancer screening. / Catalona, William J; Loeb, Stacy; Han, Misop.

In: Annals of Internal Medicine, Vol. 144, No. 6, 21.03.2006, p. 441-443.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Viewpoint

T2 - Expanding prostate cancer screening

AU - Catalona, William J

AU - Loeb, Stacy

AU - Han, Misop

PY - 2006/3/21

Y1 - 2006/3/21

N2 - Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.

AB - Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.

UR - http://www.scopus.com/inward/record.url?scp=33645648583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645648583&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-144-6-200603210-00012

DO - 10.7326/0003-4819-144-6-200603210-00012

M3 - Short survey

VL - 144

SP - 441

EP - 443

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -